Optimized Antifibrotic Therapy on Cardiac and Pulmonary Function in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review of Diagnostic and Therapeutic Approaches
Authors:
- Syndy Katherine Guarin-RiveraSGSyndy Katherine Guarin-Rivera
- Gabriela Patricia Guijarro ReinosoGRGabriela Patricia Guijarro Reinoso
- Norma Susana Chávez VillagómezNVNorma Susana Chávez Villagómez
- Jonattan Palacios TorresJTJonattan Palacios Torres
- Dario Javier Caguate MirandaDMDario Javier Caguate Miranda
- Nicole Carolina Sotomayor PáezNPNicole Carolina Sotomayor Páez
- Alexander David SilvaASAlexander David Silva
- Edgar Felipe Carranza VargasEVEdgar Felipe Carranza Vargas
- Pedro Ergir Tomay MadrigalPMPedro Ergir Tomay Madrigal
Open Access
- 7 February 2025
- journal article
- review article
- Published by Salud, Ciencia y Tecnologia in Salud, Ciencia y Tecnología
- Vol. 5, 1417
Abstract
Idiopathic Pulmonary Fibrosis (IPF) is progressive interstitial lung disease which is characterized by fibrosis of lung tissue which impair respiratory function and is seen with high mortality. Our systematic review evaluates impact of optimized antifibrotic therapies while including pirfenidone, nintedanib, and BI 1015550 on pulmonary and cardiac function in IPF patients. Comprehensive analysis with previous randomized controlled trials, cohort studies and observational data was performed to assess efficacy in slowing forced vital capacity (FVC) decline, improving prognosis and managing adverse events. Our findings indicate that antifibrotic therapies can mitigate FVC decline and reduce mortality with pirfenidone and nintedanib have shown tolerable safety profiles. BI 1015550 have also shown promising results in preventing FVC reduction and pulmonary rehabilitation alongside antifibrotic treatment improved endurance but not functional capacity. Reported limitations of the included studies include variability in study designs and potential biases from non-randomized trials. Despite these challenges antifibrotic therapies represent a critical advancement in IPF management preserving lung function and potentially enhancing quality of life.Keywords
This publication has 14 references indexed in Scilit:
- Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trialThorax, 2023
- Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary FibrosisClinical Therapeutics, 2023
- Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2022
- Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary FibrosisChest, 2021
- Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic TreatmentAdvances in Therapy, 2020
- Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patientsTherapeutic Advances in Respiratory Disease, 2020
- Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosisTherapeutic Advances in Respiratory Disease, 2020
- Real-Life Experience With Pirfenidone in Idiopathic Pulmonary Fibrosis in Argentina. A Retrospective Multicenter StudyArchivos de Bronconeumología, 2018
- Risk Factors for the Development of Idiopathic Pulmonary Fibrosis: a ReviewCurrent Pulmonology Reports, 2018
- Optimizing quality of life in patients with idiopathic pulmonary fibrosisTherapeutic Advances in Respiratory Disease, 2017